Skip to main content
logo
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
443.16
+10.09 (2.33%)
Mar 30, 2026, 4:00 PM EDT - Market closed

Vertex Pharmaceuticals Revenue By Geography

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
United States
7.29B7.03B6.82B6.68B6.42B6.26B6.16B6.04B
United States Growth
13.58%12.27%10.75%10.67%8.37%7.47%7.35%5.98%
Europe
3.41B3.42B3.31B3.45B3.36B3.28B3.27B3.11B
Europe Growth
1.47%4.31%1.34%11.09%9.68%8.30%13.50%14.91%
Other
991.70M939.20M958.10M881.30M846.30M798.40M759.30M719.80M
Other Growth
17.18%17.64%26.18%22.44%26.86%22.36%28.11%36.87%

Revenue By Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.31B10.46B10.39B10.29B10.19B9.81B9.50B9.29B
Trikafta and Kaftrio Growth
1.18%6.67%9.44%10.80%13.95%13.59%13.46%15.77%

Operating Expense Breakdown

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Research and Development
3.91B3.93B3.83B3.82B3.63B3.46B3.39B3.21B
Research and Development Growth
7.69%13.84%13.05%19.05%14.78%13.98%18.24%19.67%
Selling, General, and Administrative
1.75B1.64B1.57B1.52B1.46B1.46B1.35B1.24B
Selling, General, and Administrative Growth
19.72%12.91%16.52%22.60%28.83%40.67%32.41%27.57%
Acquired In-Process Research and Development
133.00M164.00M124.50M4.57B4.63B4.56B4.60B256.80M
Acquired In-Process Research and Development Growth
-97.13%-96.40%-97.29%1,680.14%778.09%757.06%802.47%-44.25%
Change in Value of Contingent Consideration
2.10M-2.20M1.80M-500.00K-49.60M-48.70M-49.80M
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.